Antibiotic stewardship in pediatric emergency care has long been complicated by the temptation to treat wheezing children with broad-spectrum antibiotics, partly because atypical bacterial infections can mimic or exacerbate viral-triggered episodes. A definitive answer on whether azithromycin — a macrolide antibiotic with both antimicrobial and anti-inflammatory properties — genuinely helps preschool-aged children presenting with acute wheezing would have meaningful implications for how millions of pediatric ER visits are managed each year.
Published in the New England Journal of Medicine, this editorial responds to trial evidence evaluating azithromycin versus placebo in preschoolers presenting to the emergency department with acute wheezing. The editorial's position, reflected clearly in its title, is that the evidence does not support azithromycin use in this population. The finding is particularly pointed given that macrolides were previously considered a plausible intervention: their immunomodulatory effects on airway inflammation had generated genuine scientific interest, and some earlier smaller studies suggested modest benefit. The NEJM editorial synthesizes the clinical trial data and concludes the treatment offers no meaningful advantage in acute episodes.
This conclusion carries weight beyond a single editorial. Azithromycin is one of the most commonly prescribed antibiotics globally, and its use in young children with respiratory illness — most of which is viral in origin — has been a persistent driver of antimicrobial resistance. Macrolide resistance in Streptococcus pneumoniae and Mycoplasma pneumoniae has risen steadily over the past two decades, in part due to liberal prescribing practices. A clear NEJM-level rejection of azithromycin for preschool wheezing aligns with broader antimicrobial stewardship goals and should reinforce emergency department protocols that discourage empirical antibiotic use in this age group. Clinically, this is a confirmatory and stewardship-strengthening finding rather than a paradigm shift, but its institutional authority makes it practically significant for guidelines and prescriber behavior.